Salah-Eddin Al-Batran

@salahAlBatran

Arzt, Forscher, Migrant

Frankfurt on the Main, Germany

Joined October 2020

14 Following

88 Followers

6 Posts

Salah-Eddin Al-Batran @salahAlBatran

about 4 years ago

Good to see that the IKF supported PREVENT FLOT9/HIPEC study, a study that is very difficult to recruit, has gained speed in recruitment: Preventive HIPEC with FLOT versus FLOT alone for resectable diffuse type gastroesophageal cancer by Thorsten O. Götze and Pompiliu Piso

salahAlBatran's tweet photo. Good to see that the IKF supported PREVENT FLOT9/HIPEC study, a study that is very difficult to recruit, has gained speed in recruitment: Preventive HIPEC with FLOT versus FLOT alone for resectable diffuse type gastroesophageal cancer by Thorsten O. Götze and Pompiliu Piso https://t.co/9B5kmoO5Ew

Salah-Eddin Al-Batran @salahAlBatran

about 4 years ago

IKF is happy to announce that the ADVACE study has recruited its first patient. The IIT led by Prof. Arndt Vogel evaluates an innovative combination of Atezolizumab and Derazantinib for pts with bile duct cancer and FGFR fusions/rearmaments

salahAlBatran's tweet photo. IKF is happy to announce that the ADVACE study has recruited its first patient.
The IIT led by Prof. Arndt Vogel evaluates an innovative combination of Atezolizumab and Derazantinib for pts with bile duct cancer and FGFR fusions/rearmaments https://t.co/KFB516APYC

Salah-Eddin Al-Batran @salahAlBatran

over 4 years ago

ESMO 2021 Our data on gastric/GEJ cancer patients with MSI from DANTE trial show that path response (TRG1a/b) following FLOT+Atezo was at 80%, including 50% complete path response. This is the highest path response rate seen in this disease ever. #ESMO21 #oncology #gastriccancer